Saniona AB represents a strong commitment to advancing innovative therapies in the field of rare diseases and CNS disorders. The company's core values revolve around scientific excellence, integrity, and collaboration. With a focus on delivering tangible benefits to patients and society, Saniona AB ensures rigorous research and development processes to bring breakthrough treatments to market. Their corporate philosophy centers on patient-centeredness, continuous learning, and inclusivity. Saniona AB's dedication to pioneering treatments and improving patients' lives exemplifies their vision to become a leading biopharmaceutical company within their therapeutic areas of expertise.

Saniona AB is primarily present in countries and regions such as United States, Denmark, and Sweden. The company has a strong presence in these areas, enabling it to leverage key markets for its pharmaceutical and biotechnology products. Saniona AB's focus on these regions allows the company to tap into advanced healthcare systems, research facilities, and a supportive regulatory environment. This strategic approach enables Saniona AB to drive innovation, collaborate with industry leaders, and deliver cutting-edge solutions to improve patients' lives.

Saniona AB has achieved several significant milestones. In recent years, the company has successfully advanced its pipeline and made notable progress in developing innovative treatments. Saniona AB has received regulatory approvals for clinical trials, demonstrating its commitment to bringing novel therapies to market. Furthermore, the company has formed strategic collaborations with renowned partners to enhance its research and development efforts. These achievements highlight Saniona AB's dedication to driving scientific and medical advancements in the field.

Saniona AB is a biopharmaceutical company that specializes in the research and development of innovative treatments for diseases with significant unmet needs. Founded in 2011, Saniona AB has its headquarters in Copenhagen, Denmark. With a focus on rare diseases, the company utilizes its proprietary ion channel drug discovery platform to identify and develop novel therapies. Saniona AB has a diverse pipeline of drug candidates targeting various indications, including genetic disorders and central nervous system conditions. The company's commitment to advancing scientific knowledge and improving patient outcomes has positioned it as a key player in the biopharmaceutical industry. Saniona AB continues to grow and collaborate with partners globally to bring its innovative therapies to market.

The main competitors of Saniona AB in the market include companies such as Evotec AG, BioMarin Pharmaceutical Inc., and Neurocrine Biosciences, Inc.

Saniona AB is primarily active in the pharmaceutical industry.

Saniona AB operates under a business model focused on research and development within the biotechnology industry. The company primarily develops innovative medicines targeting diseases with high unmet medical needs. Saniona AB specializes in utilizing its expertise in ion channels, which are proteins that play a significant role in various diseases. By identifying and targeting specific ion channels, the company aims to develop effective therapies for indications such as rare genetic disorders, neurological diseases, and eating disorders. Saniona AB's commitment to research and development, along with its focus on ion channels, enables it to create potential breakthrough treatments for patients in need.

Det Saniona P/E-forhold er -0,08.

Saniona KUV er 0,56.

AlleAktien Kvalitetsscore for Saniona er 5/10.

Den forventede Saniona omsætning er 466,63 mio. SEK.

Den forventede Saniona indtjening er -3,34 mia. SEK.

Saniona AB is a Swedish biotechnology company focused on developing drugs for rare diseases of the nervous system. The company was founded in 2011 and is headquartered in Copenhagen, Denmark. Saniona is listed on the Swedish stock exchange (stock: SANION) and has a market capitalization of around SEK 5.5 billion. The company's activities include research and development, clinical trials, licensing agreements, and collaborations with other companies. Saniona is dedicated to discovering and developing innovative therapies for rare nervous system diseases that currently have no or inadequate treatment options. Its main product, Tesomet, is a medication for the treatment of Prader-Willi syndrome, a rare genetic disorder that can cause obesity, metabolic problems, and other serious health issues. Tesomet has successfully passed clinical trials and received approval from the US Food and Drug Administration (FDA) for a phase 3 study. Saniona is also working on developing other drugs for rare diseases, including hyperekplexia and Huntington's disease, which are currently in preclinical or clinical development phases. Collaboration with other companies and organizations is an integral part of Saniona's business model. The company has entered into licensing agreements with major pharmaceutical companies such as Boehringer Ingelheim, Cadent Therapeutics, and Medix Biochemica, allowing Saniona to leverage its research and development expertise to develop drugs marketed by these companies. In addition to licensing agreements, Saniona also collaborates with academic institutions and other biotechnology companies to expand its research capabilities and harness the potential of its technologies. In recent years, Saniona has successfully conducted funding rounds to expand its operations. The company has raised hundreds of millions of dollars to accelerate its research and development, expand its clinical trials, and support its market entry activities. In summary, Saniona's business model is based on the discovery and development of innovative therapies for rare nervous system diseases that are currently under-treated. The company collaborates closely with other companies, academic institutions, and organizations to expand its research and development capabilities and establish potential partnerships and licensing agreements. With a successful funding round and the approval of Tesomet for phase 3 trials, Saniona is well positioned to drive future growth and develop innovative therapies for rare nervous system diseases.

Saniona udbetaler et udbytte på 0 SEK fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for Saniona, eller selskabet udbetaler ikke udbytte.

ISIN'en for Saniona er SE0005794617.

WKN for Saniona er A110VV.

Tickeren for Saniona er SANION.ST.

I løbet af de sidste 12 måneder betalte Saniona en dividende på . Dette svarer til et dividendeudbytte på omkring . For de kommende 12 måneder vil Saniona sandsynligvis betale en dividende på 0 SEK.

Udbytteafkastet for Saniona er i øjeblikket .

Saniona betaler kvartalsvis udbytte. Dette uddeles i månederne .

Saniona betalte udbytte hvert år i løbet af de sidste 0 år.

For de kommende 12 måneder forventes der dividender på 0 SEK. Dette svarer til et dividendeafkast på 0 %.

Saniona bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på Saniona fra den 10.7.2024 på 0 SEK, skulle du have haft aktien i din portefølje før ex-datoen den 10.7.2024.

Udbetalingen af det sidste udbytte blev foretaget den 10.7.2024.

I løbet af 2023 udbetalte Saniona 0 SEK i form af dividender.

Udbytterne fra Saniona udbetales i SEK.